Tizalud

Quick links to important sections

Tizalud

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tizalud

Tizalud is a prescription-only medication whose composition and functional classification define its use in managing symptoms of chronic muscle stiffness. It operates strictly as a central nervous system agent.

Property Description
Active ingredient Tizanidine Hydrochloride (Tizanidine)
Form Oral tablet or capsule
Pharmacological class Centrally acting skeletal muscle relaxant; alpha2-adrenergic agonist
Common use Relief of increased muscle tone and spasticity
Origin Synthetic, Imidazoline derivative

Tizalud: Defining the Active Substance and Type

Tizalud is a prescription-only medicine whose active compound is Tizanidine Hydrochloride (INN: Tizanidine), a chemically synthesized substance derived from the imidazoline family. It is classified pharmacologically as a centrally acting skeletal muscle relaxant and an alpha2-adrenergic agonist. Its therapeutic action occurs within the central nervous system, particularly the spinal cord, distinguishing it from agents that directly affect muscle fibers.


What is the Pharmacological Action and General Purpose?

The primary purpose of Tizanidine is the management and relief of increased muscle tone and involuntary stiffness, a state clinically recognized as spasticity.

Its mechanism is centered on stimulating alpha-2 receptors in the spine, which results in the inhibition of excitatory amino acids released by motor neurons. By dampening this excessive nerve signaling, the drug helps to normalize reflex pathways. This action is applied in scenarios where patients experience persistent tightness, and its selective action is utilized to reduce this chronic hypertonia.


Physical Form and Composition

The medication is a single-ingredient product intended for oral administration. Tizanidine Hydrochloride is commercially supplied as an immediate-release tablet or a capsule formulation. The availability in both forms provides distinct delivery profiles, which is a feature considered during prescribing. The final physical composition consists solely of the active Tizanidine Hydrochloride compound combined with various non-active, solid-form excipients necessary to create the final oral dosage unit.

Regulatory References

  1. Tizanidine - StatPearls - NCBI Bookshelf

What side effects are possible with Tizalud?

Possible Side Effects and Safety Information

The safety profile of Tizalud (Tizanidine) is structured by governmental regulatory authorities to classify potential adverse reactions based on frequency and affected body system. These official classifications reflect data gathered from clinical studies and post-marketing surveillance.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by the likelihood of occurrence:

  • Very Common: Dry mouth, somnolence (drowsiness), asthenia (weakness or fatigue), and dizziness. These are often dose-related effects.
  • Common: Hypotension (low blood pressure), bradycardia (slow heart rate), gastrointestinal disturbances, and increases in liver enzyme levels (transaminases).
  • Serious Adverse Reactions (Frequency Not Known): Severe, though rare, reactions documented in regulatory sources include hepatotoxicity (liver injury, including hepatic failure), severe hypotension, and hypersensitivity reactions such as angioedema or anaphylaxis.

System-Organ-Class Safety Notes

The most commonly affected physiological systems are the Nervous System (somnolence, dizziness, occasional hallucinations) and the Vascular/Cardiac System (hypotension, bradycardia). Furthermore, the official profile documents a risk of Hepatobiliary Disorders, requiring monitoring for liver enzyme elevations.

Exposure and Population Safety Constraints

Safety data specifies that central nervous system effects are often most prominent upon initiation of treatment or during dose escalation. A key safety constraint noted in labeling is the potential for rebound hypertension and tachycardia if the medication is stopped abruptly, especially following long-term use. Tizanidine is contraindicated in individuals with severe hepatic impairment, and caution is advised in older adults and patients with renal impairment due to reduced drug clearance.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the Tizalud (Tizanidine) overdose profile based on its documented effects on the central nervous system and cardiovascular system. There is no specific antidote known for Tizanidine overdosage; therefore, treatment is confined to symptomatic and supportive management.


Documented Overdose Manifestations

System Affected Clinical Presentation (Documented)
Central Nervous System Depressed consciousness (somnolence, confusion, lethargy, stupor), progressing to coma and extreme tiredness.
Cardiovascular System Marked hypotension (low blood pressure) and bradycardia (slow heart rate), potentially leading to circulatory collapse.
Respiratory System Respiratory depression and the risk of respiratory failure.

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose. Regulatory documents mandate that emergency services be contacted immediately if the person has collapsed, is experiencing a seizure, has trouble breathing, or cannot be awakened. Overdose management requires ensuring the adequacy of an airway, administering supportive therapy, and continuous cardiac monitoring due to the risk of severe hemodynamic instability. Caution regarding increased severity is noted in pediatric patients and those with renal impairment.

Therapeutic Uses of Tizalud

What Tizalud Treats: Main Uses and Benefits

Tizalud is generally used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed. The medication is applied in contexts marked by increased discomfort where short-term symptom management is appropriate. This includes conditions associated with muscle spasms, skeletal muscle hypertonia, and spasticity caused by neurological disorders.


Addressing Acute Symptom Clusters

Tizalud is commonly used to help address symptom clusters that may become intense or disruptive. It contributes to easing the overall symptom load, and is relevant when short-term symptomatic assistance is needed during acute episodes. It plays a role in managing symptoms related to increased discomfort or tension.


Support for Episodic Discomfort

This medication is applied in conditions characterized by periods of heightened symptoms, such as recurrent or episodic manifestations. It may assist with maintaining functional stability and helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Heightened Muscle Tension Tizalud is commonly used across conditions presenting with acute episodes where symptoms create noticeable physiological strain.


Easing Day-to-Day Symptomatic Burden

Tizalud is applied in scenarios where additional management of discomfort is required when symptoms interfere with daily comfort. It supports general well-being during symptomatic phases, providing supportive relief when symptoms become temporarily overwhelming.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tizalud — Official Regulatory Information


Populations for whom use is allowed (as stated in label):

  • Adults (18 years and older).

Populations for whom use is contraindicated:

  • Patients concurrently taking the potent CYP1A2 inhibitors fluvoxamine or ciprofloxacin.
  • Patients with a known hypersensitivity to Tizanidine or its formulation ingredients.
  • Patients with significantly impaired hepatic function.
Age-Related Rules Organ Function Restrictions
Pediatric (Under 18): Safety and efficacy have not been established; use is not recommended. Severe Renal Impairment ( CrCl < 25 mL/min): Use with caution is required due to reduced clearance.
Geriatric Use: Use with caution is advised, as drug clearance is often decreased, potentially increasing the risk of adverse effects. Hepatic Impairment: Avoid or use with extreme caution; requires periodic monitoring of aminotransferase levels (ALTs).

Pregnancy and Lactation Eligibility Status:

  • Pregnancy: Not recommended unless the potential benefit clearly outweighs the potential risk (FDA Category C).
  • Lactation: Should not be used by breastfeeding women.

Connection to the overall eligibility profile: Regulatory documents strictly define eligibility by imposing absolute prohibitions (contraindications) for concurrent use of strong enzyme inhibitors and in patients with severe hepatic disease. Use is also restricted by age, as the drug is not recommended for children and adolescents, and requires specific caution in the elderly and those with renal impairment, due to altered drug clearance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes interactions based solely on official government regulatory documents.


Contraindicated and Exposure-Modifying Combinations

Tizalud (Tizanidine) is primarily metabolized by the enzyme CYP1A2. Concomitant use with strong CYP1A2 inhibitors, specifically Fluvoxamine and Ciprofloxacin, is officially contraindicated. These combinations result in a substantial increase in Tizanidine exposure, which can lead to profound hypotension and excessive sedation.

Moderate CYP1A2 inhibitors, such as certain antiarrhythmics or hormonal contraceptives, may also significantly increase Tizanidine concentration, and their co-administration is generally not recommended or requires close supervision.

Conversely, strong CYP1A2 inducers, such as Rifampicin, can decrease Tizanidine concentration by approximately 50%, which may reduce the expected therapeutic effect.

Pharmacodynamic and Additive Effects

Interactions involving enhanced effects independent of drug concentration are also documented. Co-administration with other Central Nervous System (CNS) depressants, including alcohol, can result in additive effects, increasing the risk of sedation and drowsiness. Tizanidine can potentiate the blood pressure-lowering effects of antihypertensive medicines due to its own alpha-2 adrenergic agonist properties, potentially causing hypotension.

Non-Drug Product Considerations

The absorption of Tizanidine is known to be altered by food depending on the specific product formulation (tablet vs. capsule). Use with alcohol is specifically noted for increasing the risk of CNS depression and adverse events.

Mechanism of Action

alpha2-Adrenergic Receptor Agonism and Spinal Inhibition

The mechanism of Tizanidine begins with alpha2-adrenergic receptor agonism (alpha2-ARs), which are densely located on presynaptic neurons, primarily in the spinal cord. This specific molecular interaction is the essential first step, triggering a cascade that leads to presynaptic inhibition—a process that significantly reduces the release of excitatory neurotransmitters like glutamate and aspartate from spinal interneurons. This key action modulates neural signaling within motor pathways.


Suppression of Spinal Reflex Pathways

The core physiological consequence of Tizanidine's action is the targeted suppression of polysynaptic reflex pathways in the spinal cord, which are component parts of the circuits governing muscle tone. By diminishing the amount of excitatory signaling in these circuits, the drug lowers the excitability of the efferent motor neurons. This process directly results in the physiological change of reduction of skeletal muscle tone and decrease in the resistance of muscle to stretch.

Dosage and Administration Information

How Tizalud is Used: Official Administration Guidelines

Tizalud (Tizanidine) is administered orally and is supplied as an immediate-release tablet (2 mg, 4 mg) or capsule (2 mg, 4 mg, 6 mg). The official use protocol for this medication is strictly defined by a controlled, incremental titration schedule.


Standardized Dosing and Frequency

The initial dosage is 2 mg per dose, taken up to three times per day (every 6 to 8 hours), with timing aligned to periods when spasticity relief is most functionally critical. Dosage is increased gradually in increments of 2 mg to 4 mg per dose, with adjustments occurring every 1 to 4 days. The total daily administration must not exceed the absolute maximum of 36 mg.

Procedural Requirement Official Guideline
Consistency with Food Administration should be consistent relative to food intake (always fed or always fasted) because food consumption affects the rate of absorption.
Discontinuation The medication must be tapered gradually when ceasing treatment, typically by reducing the dose by 2 mg to 4 mg per day.
Special Populations Patients with renal or hepatic impairment require lower individual doses during titration, and subsequent dose increases should favor a larger single dose over increased frequency.

This protocol mandates a structured, step-wise titration approach to establish the minimal effective amount while strictly adhering to the daily maximum. Adherence to consistent dosing conditions and the required gradual taper upon cessation are essential components of the official administration procedures.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Tizalud


Evidence for Use in Chronic Muscle Spasticity

Tizalud was evaluated in research exploring chronic muscle spasticity, a condition characterized by increased muscle tone that often follows damage to the central nervous system, such as in individuals with Multiple Sclerosis (MS) or those recovering from a Spinal Cord Injury (SCI). Research evaluating this use primarily relies on short-term randomized controlled trials (RCTs). These studies were generally conducted with adult populations and compared Tizalud against an inactive placebo or, in some cases, other centrally acting muscle relaxant agents.

The research monitored several outcomes related to physical discomfort and changes in muscle stiffness. Specifically, studies examined changes in muscle tone and stiffness using standardized clinical rating tools, which contributed to research that describes how symptoms evolved in the observed populations over defined time intervals. Studies reported measurements of changes in spasticity scores during the study period.

Evidence for Use in Muscle Tension Associated with Regional Pain

Research was conducted in contexts involving episodic or acute changes, focusing on muscle tension or spasms related to regional pain syndromes like low back pain. The evidence in this area often comes from short-term clinical trials which studied episodes of increased symptom activity. These studies primarily enrolled adults experiencing acute pain of short duration, where researchers examined outcomes related to physical discomfort, such as changes in pain intensity over brief periods.

These findings are part of the broader evidence landscape regarding centrally acting muscle relaxants for these acute symptoms. The studies report how symptoms evolved within the specific, short-term research setting. However, the evidence quality varies across studies, and the findings have sometimes been mixed, particularly when Tizalud is evaluated against other pharmacological agents grouped together in systematic reviews.


Study Duration and Long-Term Follow-up

The majority of high-quality clinical evaluation data for Tizalud comes from studies with limited follow-up durations, primarily focused on assessing short-term changes over several weeks. While initial clinical trials described patterns related to short-term changes, there is limited information for long-term outcomes or data on the durability of effect. Research describing long-term effects is not fully established by existing studies, meaning the data primarily helps contextualize how patients reported their experience within the trial setting, not over years.

What Remains Uncertain About the Evidence

Several key research limitation frames affect the overall picture of Tizalud's clinical evaluation. Data for certain groups remain insufficient, particularly for pediatric patients and the impact of existing comorbidities. Also, the evidence for sustained evaluation of outcomes reflecting daily functioning or activity level is less defined, and long-term effects are not fully established due to limited follow-up durations. Findings related to regional pain are often mixed and evidence quality varies across studies, indicating areas where additional research is needed for clearer context.

Frequently Asked Questions (FAQ)

Common questions about Tizalud (FAQ)


Q: How quickly should I expect Tizalud to start working?

Studies on Tizalud indicate that the drug's effect generally reaches its peak concentration, or maximum strength, approximately one to two hours after a dose is taken. The effects then typically begin to fade between three and six hours after administration.


Q: Can Tizalud be taken with food, or does it need to be on an empty stomach?

Official guidelines state that Tizalud can be taken either with food or without food. However, regulatory documents describe that administration should be consistent relative to food intake because food consumption affects the rate at which the drug is absorbed into the body.


Q: What is the difference between Tizalud and [similar drug]? (informational only)

Regulatory documents classify Tizalud as a centrally acting alpha2-adrenergic agonist, a specific class of medication that acts in the central nervous system. This category includes other medications like clonidine. Official information notes that Tizalud has a significantly lower potency than clonidine in its ability to lower blood pressure.


Q: Is Tizalud a schedule IV controlled substance?

Official prescribing information states that Tizalud is not classified as a controlled substance under the regulatory scheduling system in the United States (DEA). It is a prescription-only medication.


Q: What is the general duration of effect for a single dose of Tizalud?

Based on pharmacokinetics, the duration of Tizalud’s muscle-relaxing effect generally lasts for three to six hours after a single dose. This duration is noted in the pharmacokinetic profile.


Q: Is Tizalud safe to use if I have kidney issues?

Tizalud is eliminated from the body through the kidneys, and official information notes that drug clearance is significantly reduced in patients with severe kidney impairment. For this reason, caution is advised in this population, and lower doses are typically required.


Q: Is Tizalud safe to use if I have liver issues?

Tizalud is primarily broken down (metabolized) by the liver. Official safety constraints note that use requires extreme caution and monitoring of liver enzyme levels in patients with any liver impairment. Furthermore, the use of Tizalud is strictly prohibited (contraindicated) for individuals with severe hepatic (liver) impairment due to the risk of liver injury.


Q: What does the package insert say about using Tizalud during pregnancy?

Official prescribing information describes that Tizalud is generally reserved for use during pregnancy only when the potential benefit is judged to outweigh the potential risk. This approach is based on animal studies which showed that the drug may be associated with harm to the developing fetus.


Q: Does Tizalud interact with grapefruit juice?

Tizalud is metabolized by a specific enzyme called CYP1A2. While grapefruit juice is not specifically named in regulatory documents, it is known to contain components that can affect this type of enzyme. The use of strong enzyme inhibitors is prohibited, and other potential inhibitors could also lead to an increased concentration of Tizalud in the blood.


Q: What is the purpose of the black box warning (if applicable) for Tizalud?

Tizalud does not carry a boxed warning, which is commonly referred to as a Black Box Warning, in its official prescribing information provided by regulatory authorities.


Q: Can Tizalud affect my blood pressure?

Yes, Tizalud can affect blood pressure. Because the drug acts as an alpha2-adrenergic agonist, a known effect is the potential to cause hypotension (low blood pressure) and reduce heart rate. These effects are monitored as a precaution.


Q: Is Tizalud considered a narcotic or opioid?

No. Official documents classify Tizalud as a centrally acting skeletal muscle relaxant and alpha2-adrenergic agonist. These classifications are chemically and pharmacologically distinct from narcotic or opioid medications.


Q: How long does Tizalud stay in your system after stopping?

Tizalud has a relatively short half-life of approximately 2.5 hours. While most of the active drug is quickly metabolized, the remaining inactive byproducts are eliminated from the body, primarily in the urine, with a half-life noted to be between 20 to 40 hours.


Q: Can Tizalud be used long-term?

Tizalud is indicated for the management of muscle spasticity and is often reserved for activities and times when relief is most functionally critical due to its short duration of effect. Official clinical research documents note that the experience with long-term use, especially with higher doses, is limited.


Q: If I miss a dose of Tizalud, what generally happens?

General patient information indicates that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is usually skipped, and the regular schedule should be resumed. The recommendation is to avoid taking two doses close together.


Q: Does Tizalud have a risk of dependence or withdrawal?

Abrupt discontinuation of Tizalud, particularly after long-term use of high doses, has been shown to cause withdrawal symptoms. These symptoms may include rebound hypertension (sudden high blood pressure), tachycardia (fast heart rate), and increased muscle stiffness. The drug must be decreased slowly, according to the tapering instructions provided by a healthcare provider, to help minimize these effects.


Q: Do I need a special prescription for Tizalud?

Tizalud is a prescription-only medication. However, it is not classified as a controlled substance, meaning it does not require the specific legal documentation and tracking associated with prescriptions for controlled drugs.


Q: Is Tizalud known to cause confusion in older patients?

Official documents list confusion as a possible symptom associated with Tizalud overdose. Due to the potential for reduced drug clearance in older adults, caution is advised for this population, as the risk of common adverse effects like dizziness and somnolence may be increased.


Q: Is Tizalud used to treat anxiety?

Tizalud is officially indicated only for the management of muscle spasticity. Anxiety is not listed as an approved indication in regulatory prescribing information for this medication.


Q: Does Tizalud interact with birth control pills?

Yes, studies show that Tizalud interacts with estrogen-containing hormonal contraceptives (birth control pills). These contraceptives may reduce the drug's clearance, potentially leading to increased blood levels of Tizalud. Official guidance notes that due to the potential for increased drug levels, co-administration is typically avoided or requires dose adjustment.

How should Tizalud be stored and disposed of?

How to Store and Dispose of Tizalud

Storage and disposal instructions for Tizalud (tizanidine) are mandated by regulatory agencies to maintain the product's stability and ensure safety.

Storage Conditions

Tizanidine tablets must be stored at 25°C (77°F), which is defined as controlled room temperature, with allowed excursions between 15°C and 30°C (59°F and 86°F). The product must be kept from freezing and stored away from excess heat and moisture. The medicine must be dispensed in a tight container with a child-resistant closure and stored strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Tizalud should be disposed of through an authorized drug take-back program. If this is not available, the medication may be placed in the household trash after mixing it with an undesirable substance, such as coffee grounds or dirt, and placing the mixture into a sealed bag or container. Disposal must comply with all local, regional, and national regulations, and the medicine must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tizalud found in:

A-Z Index: